Cure Logo

The Founder’s Guide to Choosing a Preclinical CRO

View all topics

Published November 18, 2026

How to Choose a Preclinical CRO for IND-Enabling Studies - Image

Cure

Overview

How to compare bids for IND-enabling studies, vet the team that will run them, and negotiate costs and data rights before you sign.

Before testing a drug candidate in people for the first time in the United States, a biotech typically submits an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA). A preclinical contract research organization (CRO) can run studies that help the FDA assess the risks of the proposed trial.

Two CROs can quote the same toxicology study and price different work. One may include toxicokinetic analysis, which assesses how much of the drug reaches systemic circulation during a study. Another may charge separately for the analysis and the work it takes to develop and qualify the assay. The lower bid can get more expensive once you add up what it leaves out.

Before you sign, decide who will design and coordinate the work, ask each bidder to price the same scope, and put the cost of changes and your rights to the data in writing.

Define What the CRO Needs to Deliver

Start with the trial you plan to run. The FDA ties the scope and duration of nonclinical studies to the nature and duration of the proposed clinical investigation. The work a CRO delivers will sit alongside the clinical protocol and chemistry, manufacturing, and controls (CMC) information in the IND. Plan those pieces together, especially if the team developing the manufacturing process works on a separate schedule.

Sanjeev Thohan, PhD, is Chief Scientific Officer at Athysis Therapeutics, Arise Biopharma, and LatentSpace Therapeutics. A consultant and research scientist, he has helped prepare investigational new drug applications and new drug applications.

Thohan describes small molecules as the more predictable starting point. For many such programs, nonclinical safety guidance gives bidders a familiar starting point, including repeat-dose toxicology, genetic toxicology, and safety pharmacology. For biotechnology-derived products covered by ICH S6(R1), the CRO may need to address whether the test species responds to the product and whether an immune response could affect interpretation. Routine genotoxicity tests are generally unnecessary for products covered by that guidance.

For cell and gene therapies, the questions depend on the product. The CRO may need to assess where the therapy goes in the body, how long it persists, or, where relevant, its potential to form tumors. Ask bidders to explain which of those questions matter for your product and to show you comparable work their proposed team has done. The FDA has guidance on biodistribution for gene therapies and other considerations for cell and gene therapy development.

Ask bidders to explain how their proposed study duration supports the planned clinical exposure. A shorter study can look cheaper on paper and still leave a gap in what the data support. Thohan also advises asking the CRO to justify its choice of animal species and dose range, and to explain how it will interpret drug exposure alongside the toxicology findings. That explanation helps you judge whether the proposed work can inform the clinical dose rationale.

The FDA can put a Phase 1 trial on clinical hold if the IND lacks enough information to assess the risks to participants. Get the CRO’s rationale in writing before committing to a study that your filing depends on.

“A beautifully designed tox study won't save an IND if the manufacturing section can't demonstrate that the product is adequately characterized and consistent,” Thohan says. As you coordinate the CRO’s work with the manufacturing team, check how you will document the relationship between the material studied and the product you plan to use in the trial.

When you work back from a first-patient date, leave time for the FDA’s initial IND review. The agency may notify the sponsor earlier that the investigation can proceed. Otherwise, the IND takes effect 30 days after the FDA receives it, provided the agency has not placed the investigation on clinical hold.

Dale T. Umetsu, MD, PhD, Volunteer Clinical Professor at the University of California, San Francisco, advises bringing in a regulatory adviser with experience in your modality. Early FDA engagement, he says, can help you avoid paying for studies you do not need or discovering late that you left out one you do.

A pre-IND meeting is an opportunity to ask the FDA about a proposed nonclinical plan and the data needed to support the first trial. The agency also offers INTERACT meetings for eligible early-stage programs facing novel development questions. If a proposed study depends on an unresolved regulatory question, ask bidders what it would cost to revise the plan and what would happen to your reserved start date.

Give each bidder the same brief. Include the proposed clinical timeline, which studies are already complete, which work you want the CRO to take on, and which decisions still depend on FDA feedback. Ask the CRO to identify what it needs from you before work can start, such as study material or an assay transferred from another lab. A start date is only useful if both teams can meet the conditions attached to it.

Choose Who Will Coordinate the Work

A full-service CRO can give a small team one project manager, one contract, and one schedule to track. Ask which studies the firm runs itself, which it subcontracts, and who takes responsibility for a subcontractor’s work. If your program depends on a specialized assay, meet the scientists who will run it and ask about their experience with your modality.

Hiring separate providers lets you choose a specialist for each study. Your team then has to coordinate schedules, transfer samples and data, and make sure the reports can be used together. Before you split the work, name the person who will handle those handoffs and decide what happens when one lab’s delay pushes back another lab’s start date.

“One CRO means one PM, one contract, less headache,” Thohan says.

Even with a prime contractor, assign someone on your side to own the program. That person should know which decisions the CRO can make, when a change needs sponsor approval, and who will review the final reports before they go into the filing.

A full-service agreement can still leave room for a specialist. If the lead CRO proposes an outside lab, ask who selects the lab, who contracts with it, and whether you will be able to speak directly with the scientists. Follow one deliverable through the proposed arrangement. If the outside lab produces data the lead CRO needs for its report, find out who checks the data and who revises the schedule if the lab has to repeat the analysis.

Compare the Same Work Across Bids

Use one comparison sheet for all bidders. Give each study its own row and capture what the fee covers, what the CRO will bill separately, who will perform the work, and when you will get draft and final reports. Ask bidders to identify assumptions that could change the price or schedule.

Thohan points to toxicokinetic analysis as a line item worth breaking out. He advises checking whether each proposal covers method development and qualification, sample analysis, repeat analysis, and reporting. Add any separately billed items before comparing totals.

“Remember that the signed bid is not the final price,” Thohan says. “Negotiate those unit costs before you sign. Ask about unused-animal credits and what happens if their tox batch runs late.”

Get prices for changes such as an extra time point or a repeat assay. Specify who can approve a change order, when the CRO must provide a revised estimate, and when work may begin. Ask what you will owe if a study is postponed or canceled and what happens if the CRO misses a scheduled start.

Thohan says he often sees an upfront payment of 20% to 30%, followed by installments tied to milestones. Review the deposit and invoice schedule alongside the study timeline. Find out what the deposit reserves, which portion is refundable, and what triggers the next payment. If an invoice is tied to a milestone, define what counts as completion. The end of laboratory work and delivery of a final report are different milestones.

Compare the schedules the same way you compare the prices. Ask bidders to distinguish a firm slot from an estimated start date. Include time for the CRO to draft reports and for your team to review them. If you are working back from a target filing date, identify which report has the least room to slip and ask how the CRO would handle a delay there.

Check the People, Quality System, and Deliverables

Ask to meet the study director and the scientists assigned to your program. Request references from sponsors with similar work. Find out which facility will handle each study, what capacity it has on your dates, and which other parts of the program would move if the start date slipped.

The FDA generally expects Good Laboratory Practice (GLP) compliance for pivotal in vitro and in vivo studies that support an IND. Ask the CRO how it documents deviations, oversees subcontracted work, and makes study records available for inspection. For electronic records and signatures, ask which systems are subject to 21 CFR Part 11 and how the CRO manages access and changes to records.

“Documentation gaps, protocol deviations, or inconsistent sample handling can turn a scientifically sound study into a regulatory liability,” Thohan says.

Ask when the proposed facility was last inspected. If the agency issued an FDA Form 483, ask what the inspectors observed, how the CRO responded, and what corrective actions it took. Have the CRO explain whether the observations touched any of the work it would do for you.

During reference calls, ask how the CRO handled an actual problem. When a study fell behind or the scope changed, how soon did the sponsor hear about it? Who explained the impact on price and timing? Ask whether the people in the proposal are the same people those references worked with.

Put Data Rights and Exit Terms in Writing

Have a biotech contracts attorney review the agreement and statement of work together. Spell out who owns the study data, results, and inventions. Ask counsel whether you need a license to any methods or other intellectual property the CRO brings to the project.

“Carve out their background IP but get a license to use it in your regulatory filings,” Thohan says.

Specify which raw data, supporting records, and reports the CRO will deliver, in what format, and when. Agree on what your company may share with regulators, investors, and development partners. Cover confidentiality, liability for errors or repeat work, and what happens to samples, records, work in progress, and prepaid fees if the relationship ends.

If a report or dataset is incomplete, the agreement should say how the sponsor flags the issue, who fixes it, and when a corrected version is due. Clarify who retains the underlying records and how your company can retrieve them if it changes providers. The scientists who need the files should review the list of deliverables before the contract is signed.

Questions to Ask Before You Sign

  • Which comparable studies has the proposed study director led, and can we speak to a sponsor who worked with that team?

  • Which facility will do each study, which work goes to subcontractors, and who handles problems at those sites?

  • When will we receive draft reports, final reports, and underlying data, and which other studies depend on those dates?

  • What does the base price cover, what will common changes cost, and who has to approve them?

  • What do we owe if a slot slips or a study is canceled, and what data, records, and samples can we take with us?

Before choosing a bidder, ask it to walk you through one likely change, such as a repeat assay that delays a final report. Find out who decides what to do, who pays, and which dates move. Then check that the agreement reflects the answers.